Reimagining IT: Bausch Health Puts Customers First In Planning For A Data-Driven Future
An Interview With Bausch Health's Chief Information Officer Chuck Hoyt
Executive Summary
Information is the lifeblood that sustains drug development – but the ability to disperse, differentiate and make sense of it is what delivers success in the marketplace. Bausch Health Companies has decided to make global alignment through the strategic application of IT the centerpiece of its effort to shed the legacy of its acquisitive predecessor Valeant Pharmaceuticals.
You may also be interested in...
Africa’s Geographer Of Genes
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.
The Medicines Patent Pool Plots A Post-Pandemic Future: Interview With Director Charles Gore
As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.
Pacifying A Pandemic With Numbers
Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health: can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.